WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership
4.8.2026 12:00:00 EEST | Business Wire | Press release
WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership
The Natural Cycles app, a Class II medical device, uses biomarker data, including temperature and heart rate data, to identify fertile and non-fertile days, helping users prevent pregnancy without hormones while also providing fertility insights. Beyond birth control, the app also supports users through pregnancy planning, pregnancy, postpartum, and perimenopause with dedicated modes tailored to each stage of their reproductive journey.
This integration and exclusive offer advance the efforts of WHOOP in women’s health by combining continuous physiological data with clinically validated fertility technology. Women are one of the fastest-growing segments of WHOOP members, with membership growing 111% year over year. As demand grows for personalized health insights and non-hormonal reproductive health options, this integration gives WHOOP members a more seamless way to understand fertility alongside the recovery, sleep, and health insights already available through WHOOP.
"This partnership represents a commitment to supporting women's health through clinically-backed, actionable data," said Dr. Ami Bhatt, WHOOP Chief Medical Officer. "By integrating with the NC° app, we are providing our members with a seamless way to access personalized reproductive health insights, expanding WHOOP beyond performance into everyday health."
"At Natural Cycles, we're committed to making digital contraception as seamless as possible for our users," said Dr. Magda Armbruster, VP of Product at Natural Cycles. "Integrating with WHOOP removes friction from the experience by allowing members to use the wearable they already rely on to automatically capture overnight skin temperature used by the NC° app to determine daily fertility status. It's another step toward making hormone-free birth control fit more naturally into everyday life."
Membership Benefits:
- A 12-month subscription to the NC° app included with any WHOOP membership for members new to Natural Cycles.
- Automatic overnight skin temperature sharing with the NC° app through compatible WHOOP devices.
- Daily fertility status inside the world's only FDA-cleared digital birth control app.
- Features designed by Natural Cycles° to support women throughout the reproductive journey—from birth control and pregnancy planning to pregnancy, postpartum, and perimenopause.
The integration is currently available for users with WHOOP MG and 5.0 devices. WHOOP and Natural Cycles° remain committed to the highest standards of privacy and data security, ensuring that sensitive health information is managed with the utmost care.
To learn more about WHOOP, please visit whoop.com. To access visuals, please visit the Digital Press Kit.
About WHOOP
WHOOP delivers a wearable membership to help people live healthier, longer lives and unlock extraordinary potential. Through a powerful 24/7 wearable with a 14-day battery life, WHOOP provides intelligent health guidance across sleep, recovery, strain, fitness, and longevity. The health platform includes an FDA-cleared ECG, a Healthspan longevity feature, Blood Pressure Insights, and Advanced Labs blood biomarker analysis. Research shows that people who wear WHOOP daily log more than 90 additional minutes of exercise per week, get over two extra hours of sleep, and have 10% higher heart rate variability.
Trusted by millions of members worldwide including athletes, global leaders, military operators, executives, and artists, WHOOP has become a modern symbol of disciplined, intentional living. WHOOP was founded in 2012 and is headquartered in Boston. The company has raised more than $950 million in venture capital, ships to 56 countries, and operates in six languages. To learn more or start a one-month free trial, visit whoop.com and connect with WHOOP on Instagram, X, Facebook, LinkedIn, and YouTube.
About Natural Cycles°
Founded in 2013 by physicists Dr. Elina Berglund Scherwitzl and Dr. Raoul Scherwitzl, Natural Cycles is a leading women's digital health company dedicated to transforming how women understand and manage their reproductive health. The company developed the world's first FDA-cleared digital method of birth control, delivered through an app and powered by a proprietary algorithm that interprets biomarker data, including body temperature, to provide personalized cycle insights and a daily fertility status. The NC° Birth Control app is an FDA-cleared Class II medical device with six FDA clearances and has also received regulatory authorizations in Europe, Canada, Brazil, Australia, Singapore, and South Korea.
With a single subscription, the Natural Cycles app offers five dedicated modes—NC° Birth Control, NC° Plan Pregnancy, NC° Follow Pregnancy, NC° Postpartum, and NC° Perimenopause—supporting women throughout their reproductive lives. Trusted by more than six million registered users worldwide and backed by 30 peer-reviewed studies, Natural Cycles continues to pioneer science-driven, non-invasive innovations that expand access to personalized reproductive health tools and empower women to take control of their reproductive health.
Learn more at Naturalcycles.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260804399367/en/
Contacts
Press Contact
Jack Taylor Worldwide
Whoop@jacktaylorpr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 11:00:00 EEST | Press release
Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphatax's long-term vision for the future of tax technology. By bringing these transfer pric
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 10:10:00 EEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 10:00:00 EEST | Press release
Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 years, she has led global teams to achieve a 100% success rate from Phase 3 development through to FDA approval for multiple programs spanning oncology, immunology and respiratory medicine. In addition, she raised funds of around $400M as founder and CEO. Across her career she has contributed to 20 drug approvals, engaging
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 10:00:00 EEST | Press release
Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network upgrades. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803353435/en/ Adtran’s SDX 6400 Series is helping TOHKnet demonstrate how Japan’s operators can migrate to 50G PON without disrupting existing PON services. “As demand for digital services continues to grow, this trial is a key milestone for the future of fiber access in Jap
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 10:00:00 EEST | Press release
The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the project continues to captivate audiences through its
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom